A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control

While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity, and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely used for cancer therapy. In this study, we construct a recombinant IL-2 immunocytokine comprising a tumor-ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zhichen, Ren, Zhenhua, Yang, Kaiting, Liu, Zhida, Cao, Shuaishuai, Deng, Sisi, Xu, Lily, Liang, Yong, Guo, Jingya, Bian, Yingjie, Xu, Hairong, Shi, Jiyun, Wang, Fan, Fu, Yang-Xin, Peng, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713724/
https://www.ncbi.nlm.nih.gov/pubmed/31462678
http://dx.doi.org/10.1038/s41467-019-11782-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713724/
https://www.ncbi.nlm.nih.gov/pubmed/31462678
http://dx.doi.org/10.1038/s41467-019-11782-w

Ejemplares similares